AxoGen, Inc. AXGN
- Market cap
- $2.5B
- P/E
- 0.0×
Follow AXGN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.52 | 8.75 | 16.52 | 10.91 | 7.16 | 8.48 | 6.87 | 3.45 | 5.55 | 9.22 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 9.88 | 28.90 | 56.85 | 25.84 | 18.43 | 23.94 | 13.66 | 11.32 | 17.23 | 34.24 |
High Price
|
|||
| 146 | 199 | 297 | 394 | 368 | 451 | 396 | 428 | 452 | 622 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 41 | 60 | 84 | 107 | 112 | 127 | 139 | 159 | 187 | 225 |
Revenue
|
|||
| 84.27% | 84.59% | 84.60% | 83.74% | 80.78% | 81.99% | 78.51% | 76.64% | 75.79% | 74.31% |
Gross Margin
|
|||
| (14) | (10) | (22) | (29) | (24) | (27) | (29) | (22) | (10) | (16) |
EBT
|
|||
| (35.06%) | (17.29%) | (26.68%) | (27.30%) | (21.18%) | (21.19%) | (20.89%) | (13.66%) | (5.32%) | (6.97%) |
EBT Margin
|
|||
| (14) | (10) | (22) | (29) | (24) | (27) | (29) | (22) | (10) | (16) |
Net Income
|
|||
| 1 | 1 | 1 | 3 | 4 | 6 | 6 | 6 | 9 | 9 |
Depreciation
|
|||
| 1.34 | 1.81 | 2.26 | 2.72 | 2.81 | 3.09 | 3.29 | 3.71 | 4.23 | 4.89 |
Revenue/Sh
|
|||
| (0.47) | (0.31) | (0.60) | (0.74) | (0.60) | (0.65) | (0.69) | (0.51) | (0.23) | (0.34) |
Earnings/Sh
|
|||
| (0.37) | (0.28) | (0.48) | (0.51) | (0.24) | (0.33) | (0.38) | (0.13) | 0.10 | 0.02 |
Cash Flow/Sh
|
|||
| (0.04) | (0.04) | (0.18) | (0.13) | (0.57) | (0.69) | (0.50) | (0.35) | (0.10) | (0.12) |
Capex/Sh
|
|||
| (0.40) | (0.32) | (0.66) | (0.64) | (0.81) | (1.01) | (0.89) | (0.48) | 0.00 | (0.10) |
Free CF/Sh
|
|||
| 0.49 | 0.76 | 3.96 | 3.37 | 3.08 | 2.73 | 2.40 | 2.23 | 2.35 | 2.80 |
Book Value/Sh
|
|||
| 31 | 33 | 37 | 39 | 40 | 41 | 42 | 43 | 44 | 46 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 6.65 | 15.41 | 9.04 | 6.58 | 6.37 | 3.03 | 3.00 | 1.86 | 3.89 | 6.69 |
PS Ratio
|
|||
| 18.31 | 36.99 | 5.16 | 5.31 | 5.81 | 3.43 | 4.12 | 3.10 | 7.02 | 11.70 |
PB Ratio
|
|||
| 6.51 | 15.22 | 7.58 | 5.65 | 5.86 | 2.85 | 3.09 | 2.06 | 4.05 | 6.79 |
EV/Sales
|
|||
| (21.59) | (87.32) | (26.00) | (24.02) | (20.43) | (8.69) | (11.47) | (15.90) | 68,961.14 | (319.81) |
EV/FCF
|
|||
| (11) | (9) | (18) | (20) | (10) | (13) | (16) | (6) | 5 | 1 |
Op' Cash Flow
|
|||
| (1) | (1) | (7) | (5) | (23) | (28) | (21) | (15) | (5) | (6) |
Capex
|
|||
| (12) | (11) | (24) | (25) | (32) | (42) | (37) | (21) | 0 | (5) |
FCF
|
|||
| 33 | 42 | 138 | 114 | 122 | 103 | 74 | 58 | 69 | 97 |
Working Cap'
|
|||
| 24 | 25 | 0 | 3 | 54 | 67 | 67 | 68 | 69 | 68 |
Total Debt
|
|||
| (6) | (12) | (122) | (99) | (57) | (23) | 12 | 31 | 29 | 22 |
Net Debt
|
|||
| 15 | 25 | 147 | 132 | 123 | 113 | 101 | 96 | 104 | 129 |
Sh' Equity
|
|||
| (34.70%) | (19.85%) | (20.45%) | (18.51%) | (13.36%) | (13.18%) | (14.35%) | (11.07%) | (4.98%) | (7.38%) |
ROA
|
|||
| (55.12%) | (37.30%) | (52.30%) | (59.53%) | (21.92%) | (17.72%) | (16.37%) | (10.61%) | (1.54%) | (3.25%) |
ROIC
|
|||
| (124.68%) | (52.09%) | (26.02%) | (20.88%) | (18.63%) | (22.90%) | (27.11%) | (22.08%) | (9.99%) | (13.49%) |
ROE
|
|||
AxoGen, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BFLY Butterfly Network, Inc. | $2.6B | 0.0× | Compare |
| UFPT UFP Technologies, Inc. | $2.3B | 31.6× | Compare |
| TMDX TransMedics Group, Inc. | $2.9B | 19.3× | Compare |
| NEOG Neogen Corporation | $3.0B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| INSP Inspire Medical Systems, Inc. | $2.0B | 15.1× | Compare |
| ESTA Establishment Labs Holdings Inc. | $2.0B | 0.0× | Compare |
| NVCR NovoCure Limited | $1.9B | 0.0× | Compare |
| IRTC iRhythm Holdings, Inc. | $3.7B | 0.0× | Compare |
AxoGen, Inc. (AXGN) key facts
- AxoGen, Inc. (AXGN) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- AxoGen, Inc. reported a net loss of $15.7 million, or a loss of $0.34 per share, for fiscal 2025.
- As of September 25, 2026, AXGN traded at $43.39, a market capitalization of $2.5 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 9.2× sales.
- Return on equity was −13.5% and debt-to-equity 0.07.
AxoGen, Inc. (AXGN) Latest News
10 Sep
Axogen raises $200 million to acquire BioCircuit and advance sutureless nerve repair technology. Major capital raise and BioCircuit acquisition represent significant strategic expansion in core nerve repair operations.
Axogen enters into definitive agreement to acquire BioCircuit Technologies. Acquisition marks major strategic expansion with potential to alter AxoGen trajectory and investor sentiment.
Axogen priced $208.7 million public offering of common stock. Large equity raise supplies growth capital while diluting shareholders and pressuring near-term stock price.
7 Aug
Axogen (AXGN) held its Q2 2026 earnings call discussing financial results, operations and outlook. Quarterly earnings calls deliver performance details and guidance that can move stock sentiment and valuation.
30 Jul
Axogen raised its 2026 outlook on a surge in breast reconstruction procedures, driving a 5.1% stock gain while leaving open whether the bull case has shifted. Raising the 2026 outlook directly improves expected financial trajectory in the core breast reconstruction business.
29 Jul
AxoGen Inc reported strong revenue growth in Q2 2026 while facing margin pressures during its earnings call. Revenue gains point to expansion but margin challenges create offsetting risks to near-term profitability.
AxoGen Q2 earnings call highlighted financial performance, revenue figures, and operational updates for the company. Q2 earnings details and guidance can shift near-term investor views on AXGN.
Axogen makes strategic investment in Trace Biosciences to advance clinical development of Nerve Trace nerve-specific imaging technology. Investment advances aligned nerve imaging technology with potential to support Axogen nerve repair operations.
AxoGen, Inc. reported its second quarter 2026 financial results. Quarterly financial results typically influence near-term investor views on performance without guaranteeing major strategic shifts.
14 May
AxoGen, Inc. (AXGN) affirms its nerve repair strategy remains unchanged amid accelerating reimbursement wins. Reimbursement momentum bolsters revenue potential and reinforces core nerve repair operations.
30 Apr
Analysts are pretty bullish on AxoGen, Inc. (NASDAQ:AXGN) stock following recent strong results. Bullish analyst sentiment after recent results poised to significantly boost investor confidence and AXGN stock trajectory.
29 Apr
AxoGen Inc (AXGN) reported strong revenue growth in Q1 2026 earnings call, despite rising expenses. Strong revenue growth positively affects financial performance, balanced by rising expenses.
28 Apr
AxoGen, Inc. (AXGN) released its Q3 2025 earnings call transcript covering financial results, operational updates, and forward-looking guidance. Q3 2025 earnings details and management commentary can significantly sway investor sentiment and AXGN's stock trajectory.
AxoGen (AXGN) released Q1 2025 earnings call transcript detailing quarterly revenue, expenses, growth metrics, and forward guidance. Q1 earnings transcript reveals key financial results and strategic updates poised to significantly sway investor sentiment and stock trajectory.
AxoGen, Inc. (AXGN) released highlights from its Q1 earnings call, detailing financial results, business updates, and forward guidance. Q1 earnings call highlights disclose key financial metrics and strategic outlook directly impacting AXGN's trajectory and investor sentiment.
AxoGen (AXGN) Q1 earnings lagged analyst estimates. Q1 earnings missing estimates highlights weaker financial results, moderately affecting investor sentiment and short-term stock performance.
Axogen, Inc. (AXGN) reported first quarter 2026 financial results. Quarterly financial results reporting moderately influences key financial performance and investor sentiment.
26 Apr
Capricorn Fund invests $22.4 million in 687,000 shares of AxoGen (AXGN), placing a huge bet on the company's nerve repair technology. Capricorn Fund's $22.4 million purchase of 687,000 AxoGen shares represents a major vote of confidence that could significantly boost investor sentiment and stock trajectory.
22 Apr
AxoGen (AXGN) released Q2 2025 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q2 earnings transcript discloses financial performance and strategic outlook capable of significantly swaying investor sentiment and stock trajectory.
21 Apr
AxoGen, Inc. (AXGN) will report earnings next week, with Wall Street expecting growth. Upcoming earnings report with expected growth may moderately influence AXGN's financial performance and investor sentiment.
14 Apr
Axogen (AXGN) valuation assessed following strong recent share price momentum, evaluating if gains are justified amid operational progress and market dynamics. Valuation analysis after price surge influences investor sentiment and stock trajectory moderately.
2 Apr
Axogen (AXGN) stands out as an investment bet due to its Zacks Rank #2 (Buy), robust 25.6% year-over-year revenue growth in Q2 2024 to $42.7 million, expanding market in peripheral nerve repair, strong surgeon adoption of Avance Nerve Graft, and projected 20%+ revenue growth through 2026 amid favorable industry dynamics. Highlights solid revenue growth and market positioning but lacks transformative events to significantly alter long-term trajectory.
21 Mar
AxoGen, Inc. (AXGN) executes a $6.5 million healthcare trim amid a 71% stock surge and 20% revenue growth. $6.5 million healthcare trim alongside 71% stock surge and 20% revenue growth represents a major strategic efficiency move boosting financial trajectory and investor confidence.
12 Mar
AxoGen announces BLA approval for Avance Nerve Graft, securing its clinical use, accelerating payer coverage negotiations, and building reimbursement momentum. BLA approval transforms Avance into a licensed biologic, unlocking superior reimbursement and market expansion for AxoGen.
10 Mar
AxoGen highlights AVANCE BLA approval and debt paydown at conference, targeting over 18% growth in 2026. AVANCE BLA approval enables product commercialization while debt paydown strengthens finances to support aggressive 2026 growth target.
5 Mar
AxoGen announces FDA BLA approval, targets 18% growth, and broader nerve repair adoption at Raymond James Conference. FDA BLA win, 18% growth target, and nerve repair expansion plans signal major regulatory and market advancements for AxoGen.
25 Feb
AxoGen (AXGN) valuation analyzed after recent share price pullback, with focus on expectations for Biologics License Application (BLA) approval. BLA expectations signal potential major regulatory milestone that could significantly boost AxoGen's trajectory and investor sentiment.
24 Feb
AxoGen, Inc. released Q4 2025 earnings call summary highlighting financial results, operational updates, and forward guidance. Q4 earnings call summary details financial performance and guidance that significantly shape investor sentiment and stock trajectory.
AxoGen (AXGN) released Q4 2025 earnings call transcript detailing financial results, operational updates, and forward guidance. Q4 earnings transcript discloses full-year financials, growth metrics, and strategic outlook significantly influencing AXGN trajectory and investor sentiment.
AxoGen Inc. (AXGN) reported strong revenue growth and strategic advancements in its Q4 2025 earnings call highlights. Strong revenue growth and strategic initiatives indicate significant positive impact on AxoGen's future performance and market trajectory.